Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + temozolomide for brain metastases from solid tumors after failure of standard treatment
ChiCTR2000039669Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and temozolomide in brain metastases, bronchial carcinoma, breast cancer and 3 more, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
anlotinibtemozolomide
03
Conditions
brain metastasesbronchial carcinomabreast cancermelanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2000039669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039669.